DEADPOOL: 10 mg/10 mg/10 mg ($65)
Overview
Deadpool is an informal market name for a three component blend containing BPC-157 and TB-500 found in WOLVERINE, along with Cartalax, which is studied in cartilage repair.
In plain terms
The first two components are the tissue-repair peptides found in the two-component pairing labeled “WOLVERINE”. The third, Cartalax, is studied for its potential to repair cartilage. It comes from an entirely different research tradition, which is what makes this combination worth describing carefully.
Cartalax belongs to a family of very short peptides developed in Russia beginning in the 1970s, under a program led by Vladimir Khavinson. The organizing idea behind that program is unusual: rather than binding a receptor on the cell surface the way most peptides do, these molecules are proposed to be small enough to enter the cell nucleus and interact directly with DNA, influencing which genes are switched on. Each peptide in the family is assigned to a particular tissue, and Cartalax is the one associated with cartilage — a tissue that is genuinely difficult to repair, since it has no blood supply and depends entirely on the cells already living inside it. As with the other blends, the three constituents have separate preclinical literatures and the combination itself has not been studied as a combination.
Technical description
BPC-157 is a synthetic pentadecapeptide (GEPPPGKPADDAGLV, MW 1419.5) with no conclusively identified cognate receptor; reported preclinical activity has been attributed to VEGFR2–Akt–eNOS signaling and nitric oxide pathway modulation. TB-500 is a synthetic fragment of thymosin β4 spanning the actin-binding domain, reported to influence G-actin sequestration, cell migration, and angiogenesis in preclinical models.
Cartalax is a synthetic short peptide bioregulator of the Khavinson (cytomedin) class, most commonly characterized as the tripeptide Ala-Glu-Asp (AED), molecular formula C12H19N3O8, MW approximately 333.3 g/mol. The sequence corresponds to a region of the alpha-1 chain of type XI collagen. Proposed mechanism is sequence-specific interaction with DNA and histone proteins leading to tissue-selective transcriptional modulation, rather than classical receptor agonism; reported endpoints in chondrocyte and fibroblast culture include altered Ki-67, p53, and caspase-3 expression and modulation of matrix gene expression. Described binding sites derive from molecular modeling rather than experimentally solved structures, and independent replication outside the originating group is limited.
- Type
- Three-component blend
- Component 1
- BPC-157 — 10 mg
- Component 2
- TB-500 (thymosin β4 fragment) — 10 mg
- Component 3
- Cartalax (AED) — 10 mg
- Total peptide mass
- 30 mg
- Appearance
- White lyophilized powder
- Storage
- Lyophilized: −20 °C, protected from light. Reconstituted: 2–8 °C.
Regulatory status
No constituent is an FDA-approved drug or a lawful dietary supplement ingredient. BPC-157 was placed in Category 2 of the FDA's bulk drug substances review in 2023, identified as raising significant safety risks for use in compounding, and both BPC-157 and TB-500 are prohibited by the World Anti-Doping Agency. Cartalax holds no marketing authorization in the United States or European Union. No combination product containing these substances holds marketing authorization in any jurisdiction. Material supplied for laboratory research is not manufactured, tested, or released under pharmaceutical standards.